Charles Schwab
INMB icon

Charles Schwab’s INmune Bio INMB Stock Holding History

Charles Schwab’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-50,252
Closed -$56.8K – 3494
2026
Q1 		$56.8K Hold
50,252
– – ﹤0.01% 3416
2025
Q4 		$78.4K Buy
50,252
+8,427
+20% +$15K ﹤0.01% 3408
2025
Q3 		$86.6K Sell
41,825
-10,000
-19% -$22.9K ﹤0.01% 3398
2025
Q2 		$120K Buy
51,825
+10,505
+25% +$77.1K ﹤0.01% 3408
2025
Q1 		$323K Buy
41,320
+6,654
+19% +$52.8K ﹤0.01% 3189
2024
Q4 		$162K Buy
34,666
+676
+2% +$3.52K ﹤0.01% 3348
2024
Q3 		$183K Sell
33,990
-3,285
-9% -$23.4K ﹤0.01% 3344
2024
Q2 		$329K Buy
+37,275
New +$367K ﹤0.01% 3340

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Charles Schwab's INMB Position: Q2 2026 in Review

Charles Schwab sold out of INmune Bio (INMB) in Q2 2026, closing a stake of 50,252 shares — an estimated $56.8K sold.

Charles Schwab first reported a position in INMB in Q2 2024 and held it in 8 quarters. The position peaked at $329K in Q2 2024. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Charles Schwab reported no remaining INmune Bio position as of Q2 2026 after selling out during the quarter.
  • Charles Schwab sold 50,252 INmune Bio shares in Q2 2026, an estimated $56.8K.
  • Charles Schwab first reported a position in INmune Bio in Q2 2024 and held it in 8 quarters.
  • Charles Schwab's INmune Bio position peaked at $329K in Q2 2024.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.